1. Home
  2. RYTM vs NPO Comparison

RYTM vs NPO Comparison

Compare RYTM & NPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • NPO
  • Stock Information
  • Founded
  • RYTM 2008
  • NPO 2002
  • Country
  • RYTM United States
  • NPO United States
  • Employees
  • RYTM N/A
  • NPO N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • NPO Metal Fabrications
  • Sector
  • RYTM Health Care
  • NPO Industrials
  • Exchange
  • RYTM Nasdaq
  • NPO Nasdaq
  • Market Cap
  • RYTM 4.3B
  • NPO 3.9B
  • IPO Year
  • RYTM 2017
  • NPO N/A
  • Fundamental
  • Price
  • RYTM $65.25
  • NPO $195.60
  • Analyst Decision
  • RYTM Strong Buy
  • NPO Buy
  • Analyst Count
  • RYTM 12
  • NPO 2
  • Target Price
  • RYTM $77.50
  • NPO $202.50
  • AVG Volume (30 Days)
  • RYTM 585.3K
  • NPO 149.4K
  • Earning Date
  • RYTM 08-05-2025
  • NPO 08-05-2025
  • Dividend Yield
  • RYTM N/A
  • NPO 0.63%
  • EPS Growth
  • RYTM N/A
  • NPO N/A
  • EPS
  • RYTM N/A
  • NPO 4.01
  • Revenue
  • RYTM $136,863,000.00
  • NPO $1,064,400,000.00
  • Revenue This Year
  • RYTM $37.56
  • NPO $4.99
  • Revenue Next Year
  • RYTM $74.99
  • NPO $5.27
  • P/E Ratio
  • RYTM N/A
  • NPO $48.92
  • Revenue Growth
  • RYTM 48.88
  • NPO 2.92
  • 52 Week Low
  • RYTM $40.46
  • NPO $133.50
  • 52 Week High
  • RYTM $69.89
  • NPO $214.58
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • NPO 58.50
  • Support Level
  • RYTM $60.80
  • NPO $189.03
  • Resistance Level
  • RYTM $64.00
  • NPO $193.41
  • Average True Range (ATR)
  • RYTM 1.96
  • NPO 4.20
  • MACD
  • RYTM -0.13
  • NPO -0.50
  • Stochastic Oscillator
  • RYTM 44.48
  • NPO 84.41

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About NPO Enpro Inc.

Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.

Share on Social Networks: